The Administrative and Biostatistics Core (Core C) has the following specific aims: 1) to provide fiscal oversight, administrative support, and scientific leadership for the entire Program;2) to promote productive communication amongst the investigators in the Projects and Cores, and between Program investigators and External Scientific Advisors;3) to provide biostatistical support to all of the Projects and Cores to aid in design and analysis of the entire Program;4) to report regularly on progress and to assure the achievement of Milestones identified in the Overview;5) to maintain communication with the Program Office and other NIAID staff members to coordinate reports and renewals per NIH requirements. Core C will be led by the Principal Investigator, Dr. Nancy L. Haigwood, and will oversee all aspects of the Program Project including scientific issues, regulatory affairs, finance, and administration of each of the Cores and Projects. This Core will ensure that expenditures and projections are commensurate with the goals of the overall project;monitor the fiscal and functional aspects of all subcontracts;and be responsible for coordinating with the Grants and Contracts Offices at participating Institutions for the disbursement, expenditure and accounting of grant funds. It will facilitate communication among Project and Core leaders, the External Scientific Advisory Board and the NIAID Program Officer and It will coordinate the preparation and submission of annual reports and renewal applications. Finally, this Core will provide linkage to a Biostatistics Unit within ONRPC who will assist in study design and data analysis and interpretation, and a project manager who will assist in all administrative and fiscal requirements of the Program Project.

Public Health Relevance

The Administrative and Biostatistics Core will provide the necessary infrastructure for the project to achieve its overall research objectives and milestones, leading to the development of HIV vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI078064-04
Application #
8377540
Study Section
Special Emphasis Panel (ZAI1-EC-A)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
4
Fiscal Year
2012
Total Cost
$56,826
Indirect Cost
$7,529
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Hessell, Ann J; Malherbe, Delphine C; Pissani, Franco et al. (2016) Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. J Immunol 196:3064-78
Nicholas, Katherine J; Greenplate, Allison R; Flaherty, David K et al. (2016) Multiparameter analysis of stimulated human peripheral blood mononuclear cells: A comparison of mass and fluorescence cytometry. Cytometry A 89:271-80
Hessell, Ann J; Haigwood, Nancy L (2015) Animal models in HIV-1 protection and therapy. Curr Opin HIV AIDS 10:170-6
Malherbe, Delphine C; Pissani, Franco; Sather, D Noah et al. (2014) Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. J Virol 88:12949-67
Pissani, Franco; Malherbe, Delphine C; Schuman, Jason T et al. (2014) Improvement of antibody responses by HIV envelope DNA and protein co-immunization. Vaccine 32:507-13
Cohen, Kristen; Altfeld, Marcus; Alter, Galit et al. (2014) Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. J Virol 88:13310-21
Sather, D Noah; Carbonetti, Sara; Malherbe, Delphine C et al. (2014) Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. J Virol 88:12968-81
Nicholas, Katherine J; Zern, Emily K; Barnett, Louise et al. (2013) B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade. PLoS One 8:e84185
Pissani, Franco; Malherbe, Delphine C; Robins, Harlan et al. (2012) Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. Vaccine 30:5519-26
Haigwood, Nancy L (2009) Update on animal models for HIV research. Eur J Immunol 39:1994-9